DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed Daiichi Sankyo

Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as DJ-927 and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of DJ-927 and capecitabine in treating patients with locally advanced or metastatic solid tumors.

Timeline

Start: 2004-02
Primary completion: 2006-01
Completion: 2006-01

Publications

Results Saif MW, Sarantopoulos J, Patnaik A, Tolcher AW, Takimoto C, Beeram M. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Dec;68(6):1565-73. doi: 10.1007/s00280-011-1639-3. Epub 2011 May 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	1250 mg/m2	—
Subject	Capecitabine	Small molecule	2500 mg/m2	—
Subject	Tesetaxel	Small molecule	18 mg/m2	Oral
Subject	Tesetaxel	Small molecule	27 mg/m2	Oral

DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Summary

Timeline

Publications

Drugs

Indications